A General Method for Making Peptide Therapeutics Resistant to Serine Protease Degradation: Application to Dipeptidyl Peptidase IV Substrates

作者：Heard Kathryn R; Wu Wengen; Li Youhua; Zhao Peng; Woznica Iwona; Lai Jack H; Beinborn Martin; Sanford David G; Dimare Matthew T; Chiluwal Amrita K; Peters Diane E; Whicher Danielle; Sudmeier James L; Bachovchin William W^*

来源：Journal of Medicinal Chemistry, 2013, 56(21): 8339-8351.

DOI：10.1021/jm400423p

Bioactive peptides have evolved to optimally fulfill specific biological functions, a fact which has long attracted attention for their use as therapeutic agents. While there have been some recent commercial successes fostered in part by advances in large-scale peptide synthesis, development of peptides as therapeutic agents has been significantly impeded by their inherent susceptibility to protease degradation in the bloodstream. Here we report that incorporation of specially designed amino acid analogues at the P1' position, directly C-terminal of the enzyme cleavage site, renders peptides, including glucagon-like peptide-1 (7-36) amide (GLP-1) and six other examples, highly resistant to serine protease degradation without significant alteration of their biological activity. We demonstrate the applicability of the method to a variety of proteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8 (DPP8), fibroblast activation protein alpha (FAP alpha), alpha-lytic protease (alpha LP), trypsin, and chymotrypsin. In summary, the "P1' modification" represents a simple, general, and highly adaptable method of generating enzymatically stable peptide-based therapeutics.

• 出版日期2013-11-14